Ozanimod NEW
| Price | $41 | $97 | $147 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Ozanimod | CAS No.: 1306760-87-1 |
| Purity: 99.74% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Ozanimod |
| Description | Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis. |
| In vitro | In S1P1R-HEK293T cells, Ozanimod induces sustained S1P1R internalization and degradation. [1] |
| In vivo | In vivo, Ozanimod shows high oral bioavailability and volume of distribution. In a MOG-induced EAE mouse model, Ozanimod (3 mg/kg, p.o.) suppresses Clinicalal symptoms. In a rat TNBS model of inflammatory bowel disease, Ozanimod (1.2 mg/kg, p.o.) inhibits Clinicalal and histological disease scores. In a Na?ve CD4+CD45Rbhi T cell adoptive transfer model, Ozanimod (1.2 mg/kg, p.o.) also significantly reduced disease severity as assessed by measuring the degree of inflammation, gland loss, hyperplasia, neutrophil infiltrate and mucosal thickness. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 16.67 mg/mL (41.21 mM), Sonication is recommended. Ethanol : 10 mg/mL (24.72 mM) |
| Keywords | RPC1063 | RPC 1063 | neurosurgery | sphingosine 1-phosphate (S1P) | LPL Receptor | inhibit | Lysophospholipid Receptor | Ozanimod | Inhibitor | multiple sclerosis (MS) | S1P receptor subtypes 5 (S1P5) | S1P receptor subtypes 1 (S1P1) |
| Inhibitors Related | Tyloxapol | Ki16198 | Siponimod | MP-A08 | S1PR1 modulator 1 |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $600.00/1g |
VIP4Y
|
Wuhan Nutra Biotechnology Co.,Ltd
|
2021-05-23 | |
| $20.00/1KG |
Longyan Tianhua Biological Technology Co., Ltd
|
2020-11-11 | ||
| $2.00/1kg |
VIP7Y
|
Career Henan Chemical Co
|
2018-12-24 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY